Quantumzyme Corp. (OTC: QTZM) has announced a breakthrough in its proprietary enzyme development platform, introducing high-performance enzymes designed to improve efficiency across pharmaceutical manufacturing processes. The new enzymes demonstrate enhanced stability, selectivity, and compatibility with lower-cost extraction solvents such as isopropyl alcohol, offering an alternative to commonly used solvents like ethyl acetate. According to the company, these characteristics may enable pharmaceutical manufacturers to reduce solvent usage, raw material costs, and downstream processing requirements while maintaining high product quality.
Preliminary internal analyses indicate that under certain manufacturing conditions, Quantumzyme's next-generation enzyme systems could support meaningful improvements in production economics. Potential drivers include reduced solvent and material costs, improved reaction efficiency and conversion rates, lower energy and purification requirements, shorter production cycles, and enhanced scalability for commercial manufacturing. The technology is particularly relevant for high-volume active pharmaceutical ingredients (APIs) and complex chiral compounds, where solvent usage and purification steps account for a substantial portion of total manufacturing costs.
“These results mark an important step forward in our efforts to modernize pharmaceutical manufacturing through advanced enzyme engineering,” stated Vighnesh Dobale, Chief Executive Officer of Quantumzyme Corp. “Our platform is designed to help manufacturers improve process efficiency and cost structure while supporting broader sustainability objectives. While results will vary by application, we believe this technology has the potential to deliver significant value across a range of pharmaceutical processes.”
The company’s recent enzyme development advancements are supported by the use of artificial intelligence and computational modeling tools designed to assist in enzyme analysis and optimization. These tools evaluate biochemical datasets, model structure–function relationships, and assess performance characteristics such as stability, selectivity, and solvent compatibility. Quantumzyme’s computational framework incorporates experimental results to refine predictive models over time, supporting incremental improvements in enzyme design and process efficiency. While these technologies may contribute to reduced development timelines and improved consistency, all enzyme candidates remain subject to laboratory validation, scale-up testing, and applicable regulatory considerations.
Quantumzyme expects to initiate pilot-scale programs and commercial collaborations with pharmaceutical manufacturing partners beginning in 2026. Multiple validation projects are currently underway to further assess performance across different use cases and production environments. This advancement reinforces Quantumzyme’s position in green chemistry and next-generation biocatalysis as the pharmaceutical industry continues to pursue more efficient, resilient, and sustainable manufacturing models.
For more information, visit Quantumzyme's website and the company’s profile on OTC Markets.
